Frustrated by the lack of tools in the cancer toolbox, Susan Galbraith, a clinical oncologist, made the jump to industry in 2001. For the next 20 years she focused on translational and early-stage oncology, first at Bristol Myers Squibb and then at AstraZeneca. Then in June, she stepped up to oversee everything from cancer drug discovery to late-stage development at AstraZeneca, as Executive Vice President of Oncology Research & Development.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Interviewed by Asher Mullard
Questions and answers have been edited for length and clarity.
